Minnesota Attorney General Keith Ellison says his office has reached a settlement with Novo Nordisk over high insulin costs.

A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Pfizer named Dr Chris Boshoff as CSO and president of R&D, effective 1st January 2025. Boshoff, previously Pfizer’s chief ...

Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...

Novo Nordisk A/S, a leading global healthcare company, and Valo Health, Inc. announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 ...

Novo Nordisk and Valo Health have entered into an expanded agreement that revolves around the discovery and development of new treatments for obesity, type 2 diabetes, and cardiovascular disease (CVD) ...

Novo Nordisk A/S has a 12-month low of $81.50 and a 12-month high of $148.15. The company has a market cap of $384.27 billion, a P/E ratio of 27.71, a PEG ratio of 1.37 and a beta of 0.45.